Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study [Gynecologic Cancer]

Conclusion
Single-agent volasertib showed antitumor activity in patients with ovarian cancer. AEs in patients receiving volasertib were mainly hematologic and manageable.

Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Pujade-Lauraine, Selle, Weber, Ray-Coquard, Vergote, Sufliarsky, Del Campo, Lortholary, Lesoin, Follana, Freyer, Pardo, Vidal, Tholander, Gladieff, Sassi, Garin-Chesa, Nazabadioko, Marzin, Pilz, Joly Tags: Chemotherapy Gynecologic Cancer Source Type: research